CellaVision receives important order from a leading Canadian laboratory
CellaVision, which develops and sells products for routine analysis of blood and other body fluids in health care, has been entrusted with delivering an order of seven automated cell morphology systems to Calgary Laboratory Services (CLS), one of the largest multi-site integrated acute care and community laboratory practices in North America. CLS is set to use CellaVision’s solution in six of their facilities, and will network cell morphology results and share patient information between them.
The order comprises seven CellaVision® DM96 analyzers for peripheral blood and body fluid analysis and the CellaVision® Remote Review Software, software which enables connectivity between six hematology labs in Southern Alberta for the purpose of centralizing hematology review and streamlining consultation. The major part of the order will be delivered during September.
“The order from CLS once again confirms our ability to provide enhanced efficiency and quality to multi-site laboratories, which are increasingly demanded by the health care sector across the world,” says Yvonne Mårtensson, CEO of CellaVision. “Our partnership provides CLS with the tools to become best practice in cell morphology and to aid in the delivery of high-quality care.”
Calgary Laboratory Services believes that CellaVision equates to technology of the future. In addition to creating efficiency and productivity into their multi-site operation, it provides more flexibility in terms of morphological assessment of samples.
“We find that it enhances our current high standard by creating increased reproducibility and eliminating the inter-observer variation, especially among reporting the RBC morphology”, states Dr. Adnan Mansoor, Division Head of Hematology and Transfusion Medicine at CLS. He goes on to say that “CellaVision offers a quick comparison to previous morphology on complex patients. Adding to the many benefits is the extensive support it will provide to the CLS teaching program.”
North America is CellaVision’s most important growth market. In 2010, North America counted for approximately 50 percent of CellaVision’s total annual sales. Since 2007, the CellaVision products are sold in Canada by the subsidiary CellaVision Canada Inc. Efficiency has long been the most important driver for meeting greater productivity requirements in North American laboratories. The growing staff shortages that exist in laboratory operations in the western world are evident in the US and Canada. Laboratories are therefore seeking solutions that ensure effective and efficient management of their large and growing sample volumes while minimizing response times.
CellaVision is an innovative, global medical technology company that develops and sells best-in-class systems for the routine analysis of blood and other body fluids. These analyses often provide critical results used in the diagnosis of a variety of illnesses such as infection and cancer. CellaVision’s products reduce manual laboratory work, standardize results and support an efficient laboratory workflow. The company has leading-edge expertise in digital image analysis, artificial intelligence and automated microscopy. In 2010, net sales were 132 MSEK and sales continue to grow with the target to increase by at least 15 % per year over an economic cycle. CellaVision has its head office in Lund, Sweden, and subsidiaries in the US, Canada and Japan. The company share is listed on Nasdaq OMX Stockholm, Small Cap. Read more at www.cellavision.com.
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.